Understanding Soft Tissue Sarcoma: Vicki L. Keedy, MD, MSCI, and Brian P. Rubin, MD, PhD

Soft tissue sarcoma is a rare cancer, estimated to be 0.7% of all new cancer cases in 2021. In this excerpt of the transcript from their continuing medical education/nursing continuing professional development (CME/NCPD)-approved activity, Virtual Tumor Board: Optimizing Personalized Care Plans for Patients with Advanced Soft Tissue Sarcoma, Vicki L. Keedy, MD, MSCI, of the Vanderbilt-Ingram Cancer Center, and Brian P. Rubin, MD, PhD, of the Cleveland Clinic, discuss the rarity of...
Continue reading

Tazemetostat Approved for Epithelioid Sarcoma

The FDA has granted accelerated approval to tazemetostat (TazverikTM, Epizyme) for the treatment of adult and pediatric patients aged 16 or older with unresectable locally advanced or metastatic epithelioid sarcoma. Epithelioid sarcoma, which often occurs in young adults and comprises less than 1% of all soft tissue sarcomas, carries a high risk of local and regional spread, and it metastasizes in approximately 30% to 50% of cases. Tazemetostat, a first-in-class selective enhancer of zeste ...
Continue reading

Soft Tissue Sarcoma In Young Versus Older Adulthood

Soft tissue sarcoma, a rare cancer in tissues that connect, support, and surround body structures, is found in various age groups and typically has a five-year survival rate of 65%. When investigators conducted research comparing the clinical presentation, histological subtype, treatment, and outcome of soft tissue sarcoma in adolescents and young adults versus older adults, they found several differences between the two populations that could aid in future research on this disease. For this stu...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.